Chimeric antigen receptor (CAR)-expressing T-cells are without a doubt a breakthrough therapy for hematological malignancies. Despite their success, clinical experience has revealed several challenges, which include relapse after targeting single antigens such as CD19 in the case of B-cell acute lymphoblastic leukemia (B-ALL), and the occurrence of side effects that could be severe in some cases. Therefore, it became clear that improved safety approaches, and targeting multiple antigens, should be considered to further improve CAR T-cell therapy for B-ALL. In this paper, we address both issues by investigating the use of CD10 as a therapeutic target for B-ALL with our switchable UniCAR system. The UniCAR platform is a modular platform that depends on the presence of two elements to function. These include UniCAR T-cells and the target modules (TMs), which cross-link the T-cells to their respective targets on tumor cells. The TMs function as keys that control the switchability of UniCAR T-cells. Here, we demonstrate that UniCAR T-cells, armed with anti-CD10 TM, can efficiently kill B-ALL cell lines, as well as patient-derived B-ALL blasts, thereby highlighting the exciting possibility for using CD10 as an emerging therapeutic target for B-cell malignancies.
- MeSH
- antigeny CD19 metabolismus MeSH
- chronická lymfatická leukemie * metabolismus terapie MeSH
- imunoterapie adoptivní MeSH
- leukemie B-buněčná * metabolismus terapie MeSH
- lidé MeSH
- neprilysin * terapeutické užití MeSH
- receptory antigenů T-buněk metabolismus MeSH
- T-lymfocyty MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- MeSH
- B-buněčný lymfom komplikace mortalita terapie MeSH
- COVID-19 komplikace MeSH
- imunoterapie adoptivní MeSH
- leukemie B-buněčná komplikace mortalita terapie MeSH
- lidé MeSH
- prognóza MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Seminars in oncology, ISSN 0093-7754 ; vol. 29, no. 1, suppl. 2, February 2002
125 s. : il., tab. ; 28 cm
- MeSH
- imunoterapie metody využití MeSH
- leukemie B-buněčná terapie MeSH
- monoklonální protilátky aplikace a dávkování terapeutické užití MeSH
- protokoly antitumorózní kombinované chemoterapie MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- onkologie
- hematologie a transfuzní lékařství
- farmakoterapie
Seminars in oncology, ISSN 0093-7754 ; vol. 26, no. 5, suppl. 14, October 1999
122 s. : il., tab. ; 28 cm
APMIS ; Supplementum Vol. 103. 52
39 s. : tab. ; 28 cm
